1. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study
- Author
-
Thiem Dinh Vu, Celine Zocchetti, Quang Dang Nguyen, Huong Thi Ai Tran, Valérie Bosch-Castells, and Guy Houillon
- Subjects
Adult ,Male ,Microbiology (medical) ,Adolescent ,030231 tropical medicine ,Dose-Response Relationship, Immunologic ,Antibodies, Viral ,Vaccines, Attenuated ,IMOJEV® ,lcsh:Infectious and parasitic diseases ,Young Adult ,03 medical and health sciences ,Immunogenicity, Vaccine ,0302 clinical medicine ,Plaque reduction neutralization test ,medicine ,Humans ,lcsh:RC109-216 ,Prospective Studies ,030212 general & internal medicine ,Seroconversion ,Child ,Encephalitis, Japanese ,Neutralizing antibody ,Reactogenicity ,biology ,Japanese Encephalitis Vaccines ,business.industry ,Immunogenicity ,Infant ,General Medicine ,Middle Aged ,Japanese encephalitis ,medicine.disease ,Antibodies, Neutralizing ,Live attenuated Japanese encephalitis vaccine ,Vaccination ,Titer ,Infectious Diseases ,Vietnam ,Child, Preschool ,Immunology ,biology.protein ,Female ,business ,JE-CV - Abstract
Objective: To describe the immunogenicity and safety of the Japanese encephalitis chimeric virus vaccine (JE-CV) in children and adults in Vietnam. Methods: In this prospective, open-label, single-center, single-arm study, 250 healthy participants aged 9 months to 60 years received a single dose of JE-CV (IMOJEV®). JE neutralizing antibody titers were assessed at baseline and 28 days after vaccination using the 50% plaque reduction neutralization test (PRNT50). Safety and reactogenicity were assessed through solicited and unsolicited adverse events. Findings: Seroconversion (titer ≥10 [1/dil] in participants JE seronegative [titer
- Published
- 2018